Red Biotechnology Market

Report Overview

The Global Red Biotechnology Market was valued at the USD 397.0 Billion in 2023 and is anticipated to register substantial market growth of the USD 678.0 Billion by 2033, with a 5.5% CAGR.

The usage of biological agents or organisms for the manufacturing of biopharmaceutical drugs, genetically modified crops, renewable biofuels, and other products is popularly identified as red biotechnology. It includes disciplines like genetics, molecular biology, biochemistry, embryology, and cell biology that are used to develop products and services in sectors like human and veterinary healthcare, agriculture, food production, and environmental management.

The factors driving the growth of red biotechnology market includes rising incidences and prevalence of chronic and rare diseases and raised funding in healthcare industry.

• According to American Cancer Society in January 2023, an estimated 1,958,310 new cancer cases occurred in United States in 2023.
• According to American Cancer Society, over 18 million Americans were reported to have a history of cancer in the year 2022.
• In January 2022, Elli lilly and Company, signed a research and collaboration agreement with Entos Pharmaceuticals to develop innovative therapies in multiple neurologic indications, using Entos’ Fusogenix nucleic acid delivery technology and Lilly’s therapeutic cargo. Under the agreement, Elli Lilly and Company will fund the USD 400 million for the developmental and commercialization of the nucleic acid based therapeutics.

Key Takeaways

• Market Size: Red Biotechnology Market was valued at the USD 397.0 Billion in 2023 and is anticipated to register substantial market growth of the USD 678.0 Billion by 2033
• Market Growth: The market is growing with 5.5% CAGR.
• Product Type Analysis: Human vaccines dominates 45.6% market share in the red biotechnology market.
• Application Analysis: Gene therapy segment dominated the global red biotechnology market, occupying a prominent market revenue share of 59.4% in the year 2023.
• End-Use Analysis: Biopharmaceutical industries dominate 62.3% market share in 2023
• Regional Analysis: North America led the global red biotechnology market, capturing a remarkable market revenue share of 42.1% in the year 2023.

By Product Type Analysis

Human vaccines dominates the red biotechnology market

Based on product type, the red biotechnology market is broadly classified into Gene Recombinant Drugs, Human Vaccines, Blood Products, Diagnostic Reagents, Personalized Medicines and Other segments. Amongst these, human vaccine segment played an instrumental role is dominating the global red biotechnology market, capturing a praise worthy market revenue share of 45.6% in the year 2023.

This is by virtue of the crucial role played by vaccines in preventing and controlling diverse diseases. Biotechnological advancements are being introduced into the manufacturing of vaccines which leads to a new way of disease prevention.

• According to World Health Organization, global vaccines market supplied 16 billion vaccine doses worth the USD 141 billion in 2021, which is almost three times the market’s volume of 5.8 billion and nearly three and a half times its value of the USD 38 billion from the previous year.

By Application Analysis

Gene therapy segment occupied a major market portion

Based on application, the market fractionates into Pharmacogenomics, Gene Therapy, Genetic Testing and Biopharmaceutical Production segment. Amongst these, gene therapy segment dominated the global red biotechnology market, occupying a prominent market revenue share of 59.4% in the year 2023. The dominance is underscored by the extensive research being carried out to enhance therapeutics for the treatment of various genetic defects responsible for rare diseases.

Furthermore, red biotechnology is useful in the arena of poultry farming and veterinary science. Additional technologies where is technology is beneficial includes cancer research, tissue engineering, biochips manufacturing and others.

By End User Analysis

Biopharmaceutical companies played an instrumental role in 2023

Based on end use, the market is broadly classified into Research Institutes, CMOs & CROs, Biopharmaceutical industries and Other segments. Amongst these, a laudable market revenue shares of 62.3% is witnessed by biopharmaceutical companies, owing to increasing R&D activities related to biopharmaceutical drugs and medications, dominating the global red biotechnology market in the year 2023.

Biopharmaceuticals include proteins, antibodies, DNA, RNA, or antisense oligonucleotides used for therapeutic or diagnostic purposes, and these products are produced by means other than direct extraction from a native biological source. A significant development in the field of medical biotechnology is noticed, including the development of gene-based therapies.

• In May 2022, Novartis received the United States Food & Drug Administration approval for Car-T cell therapy Kymriah to treat adults with relapsed or refractory lymphoma following two or more lines of systemic therapy.

Key Market Segments

By Product Type

• Gene Recombinant Drugs
• Human Vaccines
• Blood Products
• Diagnostic Reagents
• Personalized Medicines
• Other

By Application

• Pharmacogenomics
• Gene Therapy
• Genetic Testing
• Biopharmaceutical Production

By End User

• Research Institutes
• CMOs & CROs
• Biopharmaceutical industries
• Other

Market Drivers

Rising prevalence of Chronic illnesses

The global red biotechnology market witnesses a robust thrive in recent years owing to the rising incidences of cancer and other chronic illnesses. For this reason, red biotechnology employ organisms to create and produce cancer medicines and diagnostic methods. thus, due to rising number of people suffering from diseases, the industry is anticipated to excel in the upcoming years.

• According to World Cancer Research Fund Organization, there were 18,094,716 million new cancer cases worldwide in 2020. The collective age standardized rate for malignancies was 190 per 100,000, eliminating non melanoma skin cancer. Men had a greater rate (206.9 per 100,000) than women (178.1 per 100,000).

Incorporation of Artificial Intelligence & Machine Learning

Artificial intelligence has become a crucial part in biotechnology sector, essential for various activities involved in developing new drugs. Artificial intelligence and machine learning are widely implemented in the drug development process. Depending upon established target structures, machine learning enables the discovery of tiny molecules with therapeutic potential. Thus, these applications of AI in red biotechnology are expanding due to the escalating use of artificial intelligence and machine learning.

Market Restraints

In addition to human trials, various other trials are being carried out, with FDA closely monitoring each and every step of the process. Many times, the product may be proved unsustainable during these trials and may take closely 10 ten to procedure completion. In addition of this, significant technological advancements may be made during the research and development period, that could pessimistically affect the final product. Thus, to prevent the market from hampering, the market for red biotechnology may need to be improved for all these issues.

• A study by Ernst and Young found that 36% of the medications never make it past the early stages of development.
• A study by Ernst and Young, 40% of contestants were eliminated in the final round, while another 68% were required to progress through the intermediate stage.

Opportunities

Lucrative growth is anticipated in the near future due to advance technologies

The global red biotechnology market is being constantly fueled by 3D printing. Custom made products built from virtual models will hasten the growth of a more adaptable, affordable manufacturing industry for the on-demand market. A significant revolution is brought by the use of 3D printing in biomedicine, hence the future of red biotechnology lies in 3D bio-printing.

The creation of ex-Novo organs from human cells and biocompatible material, substitute allograft transplant, which often mean the difference between life and death is been executed by 3D bio-printing, leading to more accurate, less expensive experimental models instead of animal testing. This technology’s high level of innovation could mean the difference between being new and out-of-date. Thus, such technologies open up new prospects for the market growth in the upcoming days.

Latest Trends

Escalating adoption of Personalized medicines: The rising trend benefitting red biotechnology includes the adoption of personalized medicines using biomarkers, genetics, and clinical data to customize treatments for patients. Companies are highly emphasizing on research targeted biologics and precision immunotherapies that aids in selective attack towards diseased cells depending on persons’ molecular profile. For instance, Vitrakvi is a tissue agnostic precision therapy for cancers with NTRK gene fusion.

Rising adoption of AI & Big data: The usage of big data analytics and artificial intelligence is becoming extensive to streamline biologics R&D. Identification of new disease targets, prediction of clinical outcomes, design biologics and simulate trials is being done by AI, compressing timelines and costs. Bio-manufacturing yields is ameliorated by data analytics. The application of advanced computing helps to optimize biopharmaceutical process and boost productivity.

Shift to low cost biosimilar drugs: There is a notable shift towards more affordable bio-similar, providing comparable efficacy and safety. 31 bio-similar are approved between 2017 and 2021 by United States Food and Drug Administration. Increasing biosimilar adoption can expand access to essential treatments while reducing biopharmaceuticals’ costs, a trend benefitting healthcare systems globally.

Impact of Macroeconomic factors

Technological advancements in biotechnology research and development including gene editing technologies, synthetic biology and personalized medicines drive innovation in the global red biotechnology market. A competitive advantage is gained by companies, that leverage cutting-edge technologies to develop novel therapeutics and diagnostics.

Furthermore, events like pandemics or outbreak of infectious diseases can leave a significant impact on red biotechnology market, leading to scaling funding for research into vaccines, antiviral drugs, and diagnostics, for instance, COVID 19 pandemic.

Regional Analysis

North America Held the Majority of Share of the Pharmacogenomics Market.

North America led the global red biotechnology market, capturing a remarkable market revenue share of 42.1% in the year 2023. The dominance held by the region is highly attributed to the rising prevalence of chronic and rare diseases, escalating R&D activities and high technological advancements. The increase in cancer cases with increasing geriatric population eventually drive the regional market expansion.

In addition to this, the increasing expenditure both by government and market players for boosting research on genetic diseases substantially fosters the market growth.

• According to American Cancer Society, new cancer cases exceeding 1.9 million are expected to be diagnosed in United States in 2023. 88% of people diagnosed with cancer in United States are 50 or older and 57% are 65 or older.
• According to National Institute of Health article in March 2023, the spending of gene therapy was the USD 486 million in 2021 and the USD 560 million in 2022.
• According to National Centre of Health Statistics in March 2023, research investments in nucleic acid based research are expected to scale in the coming years in United States. The research funding in Genetics would likely elevate from the USD 1,615 million to the USD 12,445 million by 2024.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

The Red Biotechnology market comprises prominent key players, researchers, and companies that invest a large amount of capital to improve drug safety and effectiveness, which drives the market’s growth. This results in strong competition among various major players in the field. Government support also plays a role by funding companies working on bioinformatics technology for precision medicine research. Furthermore, various companies are launching and introducing innovative products and services that support the market’s growth.

Top Key Players in the Pharmacogenomics Market

• Pfizer Inc.
• Merck KGaA
• Amgen Inc.
• Novartis AG
• Gilead Sciences Inc.
• Takeda Pharmaceutical Company Ltd
• Regeneron Pharmaceuticals Inc.
• AstraZeneca Plc.
• CELGENE Corporation
• Biogen Inc.

Recent Developments

• Acquisition (June 2024): Pfizer Inc. acquired BioThera Solutions for $2.5 billion, enhancing its oncology and immunotherapy portfolio. This acquisition includes BioThera’s innovative cancer immunotherapies and advanced biologics manufacturing capabilities, bolstering Pfizer’s position in the red biotechnology market.
• Merck KGaA (May 2024): Merck KGaA launched GenRevive, a gene therapy for hemophilia B. This one-time treatment utilizes advanced gene editing technology to reduce bleeding episodes and significantly improve patient quality of life.
• Amgen Inc. (April 2024): Amgen Inc. merged with BioMedix Pharmaceuticals, enhancing its biologics and biosimilars development capabilities. This merger aims to accelerate the introduction of innovative therapies, particularly in oncology and inflammatory diseases.
• Novartis AG (March 2024): Novartis AG acquired GenCell Therapeutics for $3 billion, strengthening its gene therapy sector. The acquisition includes GenCell’s platform for personalized gene therapies, expanding Novartis’ pipeline for rare genetic disorders.
• Gilead Sciences Inc. (February 2024): Gilead Sciences Inc. launched ViruCure, an antiviral biologic for chronic hepatitis B. ViruCure suppresses viral replication and boosts the immune response, marking a significant advancement in Gilead’s antiviral portfolio.
• Takeda Pharmaceutical Company Ltd (January 2024): Takeda Pharmaceutical Company Ltd merged with SynBioTech, enhancing its synthetic biology and genetic engineering capabilities. This merger focuses on developing next-generation biologics and gene therapies for rare diseases, expanding Takeda’s red biotechnology presence.